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Abstract
This paper considers conducting inference about the effect of a treatment (or exposure) on an 
outcome of interest. In the ideal setting where treatment is assigned randomly, under certain 
assumptions the treatment effect is identifiable from the observable data and inference is 
straightforward. However, in other settings such as observational studies or randomized trials with 
noncompliance, the treatment effect is no longer identifiable without relying on untestable 
assumptions. Nonetheless, the observable data often do provide some information about the effect 
of treatment, that is, the parameter of interest is partially identifiable. Two approaches are often 
employed in this setting: (i) bounds are derived for the treatment effect under minimal 
assumptions, or (ii) additional untestable assumptions are invoked that render the treatment effect 
identifiable and then sensitivity analysis is conducted to assess how inference about the treatment 
effect changes as the untestable assumptions are varied. Approaches (i) and (ii) are considered in 
various settings, including assessing principal strata effects, direct and indirect effects and effects 
of time-varying exposures. Methods for drawing formal inference about partially identified 
parameters are also discussed.
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In many areas of science, interest often lies in assessing the causal effect of a treatment (or 
exposure) on some particular outcome of interest. For example, researchers may be 
interested in estimating the difference between the average outcomes when all individuals 
are treated (exposed) versus when all individuals are not treated (unexposed). When 
treatment is assigned randomly and there is perfect compliance to treatment assignment, 
such treatment effects are identifiable and inference about the effect of treatment proceeds in 
a straightforward fashion. On the other hand, if the treatment assignment mechanism is not 
known to the analyst or compliance is not perfect, then these treatment effects are not 
identifiable from the observable data.
A statistical parameter is considered identifiable if different values of the parameter give rise 
to different probability distributions of the observable random variables. A parameter is 
partially identifiable if more than one value of the parameter gives rise to the same observed 
data law, but the set of such values is smaller than the parameter space. Traditionally, 
statistical inference has been restricted to the situation when parameters are identifiable. 
More recent research has considered methods for conducting inference about partially 
identifiable parameters. This research has been motivated to some extent by methods to 
evaluate causal effects of treatment, which are frequently partially identifiable. For instance, 
causal estimands are typically only partially identifiable in observational studies where the 
treatment selection mechanism is not known to the analyst. Noncompliance in randomized 
trials may also render treatment effects partially identifiable and a large amount of research 
has been devoted to drawing inference about treatment effects in the presence of 
noncompliance. Partial identifiability also arises when drawing inference about treatment 
effects within principal strata or effects describing relationships between an outcome and a 
treatment that are mediated by some intermediate variable.
In order to conduct inference about treatment effects that are partially identifiable, two 
approaches are often employed: (i) bounds are derived for the treatment effect under 
minimal assumptions, or (ii) additional untestable assumptions are invoked under which the 
treatment effect is identifiable and then sensitivity analysis is conducted to assess how 
inference about the treatment effect changes as the untestable assumptions are varied. Below 
(i) and (ii) are illustrated in five settings. In Section 2, we consider treatment effect bounds 
and sensitivity analysis when the treatment assignment mechanism is unknown. In Section 
3, partial identifiability of principal strata causal effects are discussed. In Section 4, the 
setting of noncompliance is considered where there is interest in assessing the effect of 
treatment if there was perfect compliance. In Section 5, bounds and sensitivity analysis for 
direct and indirect effects in mediation analysis are presented, and in Section 6 longitudinal 
treatment effects are considered. Much of the literature on bounds and sensitivity analysis 
focuses on ignorance due to partial identifiability and tends to ignore uncertainty due to 
sampling error. Section 7 presents some methods that appropriately quantify this uncertainty 
when drawing inference about partially identifiable treatment effects. Section 8 concludes 
with a discussion.
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2.1 Minimal Assumptions Bounds
Suppose we have a random sample of individuals where each potentially receives treatment 
or control. Unless otherwise indicated, let Z indicate treatment received where Z = 1 denotes 
treatment and Z = 0 denotes control. Denote the observed outcome of interest by Y. In order 
to define a treatment effect on the outcome Y, we first define potential outcomes for an 
individual when receiving treatment, denoted Y(1), and when receiving control, denoted 
Y(0). Throughout this paper, we invoke the stable unit treatment value assumption (SUTVA; 
Rubin, 1980), that is, there is no interference between units and there are no hidden 
(unrepresented) forms of treatment such that each individual has two potential outcomes 
{Y(0), Y(1)}. The no hidden forms of treatment guarantees that the observed outcome is 
equal to the potential outcome corresponding to the observed treatment, namely that Y = Y(z) 
for Z = z. Here, this will be referred to as causal consistency; for further discussion of causal 
consistency see Pearl (2010) and references therein. Once an individual receives treatment 
Z, the potential outcome Y(Z) is observed and the other potential outcome (or counterfactual) 
Y(1 − Z) becomes missing. Assume that n i.i.d. copies of (Z, Y) are observed and denoted by 
(Zi, Yi) for i = 1, …, n.
In this section, we consider treatment effect bounds when the treatment assignment 
mechanism is unknown. Here, Z can be thought of as treatment selection by the individual or 
by nature, rather than random treatment assignment as in an experiment. Define the average 
treatment effect ATE to be E[Y(1) − Y(0)] = E[Y(1)] − E[Y(0)] where E denotes the expected 
value. The ATE can be decomposed as
(1)
Note E[Y(z)|Z = z] = E[Y|Z = z] by causal consistency. Thus, from the observed data E[Y(z)|Z 
= z] and Pr[Z = z] are identifiable and can be consistently estimated by their empirical 
counterparts. On the other hand, the observed data provide no information about E[Y(z)|Z = 
1 − z], such that (1) is only partially identifiable without additional assumptions.
Bounds on E[Y(1) − Y(0)] can be obtained by entertaining the smallest and largest possible 
values for E[Y(z)|Z = 1 − z]. If Y(1) and Y(0) are not bounded then bounds on E[Y(1) − Y(0)] 
will be completely uninformative, ranging from −∞ to ∞. Thus, informative bounds are 
only possible if Y(0) and Y(1) are bounded. Because any bounded variable can be rescaled to 
take values in the unit interval, without loss of generality assume Y(z) ∈ [0, 1] for z = 0, 1. 
Then 0 ≤ E[Y(z)|Z = 1 − z] ≤ 1 and from (1) it follows that E[Y(1) − Y(0)] is bounded below 
by setting E[Y(1)|Z = 0] = 0 and E[Y(0)|Z = 1] = 1, which yields the lower bound
(2)
Similarly, E[Y(1) − Y(0)] is bounded above by setting E[Y(1)|Z = 0] = 1 and E[Y(0)|Z = 1] = 
0, which yields the upper bound
Richardson et al. Page 3























These bounds were derived independently by Robins (1989) and Manski (1990). The lower 
and upper bounds (2) and (3) are sharp in the sense that it is not possible to derive narrower 
bounds without additional assumptions. Note the interval formed by (2) and (3) is contained 
in [−1, 1] and is of width 1. Thus, the bounds are informative in that the treatment effect is 
now restricted to half of the otherwise possible range [−1, 1]. On the other hand, the bounds 
will always contain the null value 0 corresponding to no average treatment effect. That is, 
without additional assumptions the sign of the treatment effect cannot be determined from 
the observable data.
2.2 Additional Assumptions
The bounds (2)–(3) are sometimes called the “no assumptions” or “worst case” bounds 
because no assumptions are made about the effect of treatment in the population (Lee, 2005; 
Morgan and Winship, 2007). The only assumptions made in deriving (2) and (3) are 
SUTVA and that the observed data constitute a random sample. If additional assumptions 
are invoked, the treatment effect bounds may become tighter (i.e., narrower) or even 
collapse to a point (i.e., the treatment effect may become identifiable). Sometimes these 
additional assumptions will have implications that are testable based on the observed data. 
Should the observed data provide evidence against an assumption under consideration, then 
bounds should be computed without making this assumption.
An example of an additional assumption is mean independence, that is,
(4)
Under (4) ATE is identifiable. Specifically the upper and lower bounds for ATE both equal 
E[Y(1)|Z = 1] − E[Y(0)|Z = 0], which is identifiable from the observable data and can be 
consistently estimated by the “naive” estimator given by the difference in sample means 
between the groups of individuals receiving treatment and control. Assumption (4) will hold 
in experiments where treatment is randomly assigned as in a randomized clinical trial. 
Moreover, in randomized experiments the stronger assumption
(5)
will hold, where ∐ denotes independence. Independent treatment assignment (5) implies 
mean independence (4).
In some settings it may be reasonable to consider additional assumptions that are not as 
strong as (4) or (5) but nonetheless lead to tighter bounds than (2) and (3). For example, 
monotonicity type assumptions might be considered, such as monotone treatment selection 
(MTS)
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MTS assumes individuals who select treatment will on average have outcomes greater than 
or equal to that of individuals who do not select treatment under the counterfactual scenario 
all individuals selected the same z. Manski and Pepper (2000) consider MTS when 
examining the effect of returning to school on wages later in life. For this example, MTS 
implies individuals who choose to return to school will have higher wages on average 
compared to individuals who choose to not return to school under the counterfactual 
scenario no individuals return to school. Alternatively, one might assume monotone 
treatment response (MTR)
(Manski, 1997). MTR assumes that under treatment each individual will have a response 
greater than or equal to that under control. For instance, suppose Z = 1 if an individual elects 
to get the annual influenza vaccine and Z = 0 otherwise, and let Y(z) = 1 if an individual 
subsequently does not develop flu-like symptoms when Z = z, and Y(z) = 0 otherwise. MTR 
asserts that each individual is more or as likely to not develop flu-like symptoms if they are 
vaccinated versus if they are unvaccinated. Given to date there is no evidence that the annual 
flu vaccine enhances the probability of acquiring influenza, MTR might be plausible for this 
example.
Assuming MTS or MTR can lead to narrower bounds than (2) and (3) because they imply 
additional constraints on unobserved counterfactual expectations. For example, assuming 
MTS, E[Y(0)|Z = 1] is bounded below by E[Y(0)|Z = 0] and E[Y(1)|Z = 0] is bounded above 
by E[Y(1)|Z = 1], implying the upper bound on E[Y(1) − Y(0)] is
(7)
for which the naive estimator is consistent. Under MTS, the lower bound remains (2). In 
contrast to the no assumptions bounds, assuming MTS the bounds may exclude 0, 
specifically when (7) is negative. MTR implies E[Y(1)] ≥ E[Y(0)] which in turn implies that 
the ATE lower bound is 0. Under MTR, the upper bound remains (3).
2.3 AZT Example
To illustrate the bounds above, consider a hypothetical study of 2000 HIV patients (from 
Figure 2 of Robins, 1989) where 1400 individuals elected to take the drug AZT and 600 
elected not to take AZT (this is a simplified version of the problem Robins considers). The 
outcome of interest is death or survival at a given time point. Of the 2000 patients, 1000 died 
with exactly 500 from each group. Let Z = 1 if the patient elected to take AZT and Z = 0 
otherwise; let Y = 1 if the individual died and 0 otherwise. The naive estimator, that is, the 
difference in sample means between Z = 1 and Z = 0, equals 500/1400 − 500/600 ≈ −0.48. 
The empirical estimates of the no assumptions bounds (2) and (3) equal −0.7 and 0.3. In this 
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setting, the MTS assumption (6) supposes that individuals who elected to take AZT would 
have been more or as likely to die as individuals who did not take AZT in the counterfactual 
scenarios where everyone receives treatment or everyone does not receive treatment. This 
might be reasonable if it is thought that those who took AZT were on average less healthy 
than those who did not. Assuming MTS, the upper bound (7) is estimated to be −0.48. Thus, 
in this example the MTS bounds are substantially tighter than the no assumption bounds. 
The estimated MTS bounds lead to the conclusion (ignoring sampling variability, a point 
which we return to later) that AZT reduces the probability of death by at least 0.48 whereas 
without the MTS assumption we cannot even conclude whether the effect of treatment is 
nonzero.
2.4 Sensitivity Analysis
Assumptions such as (4) or (5) which identify the ATE, or assumptions such as MTS which 
sharpen the bounds, cannot be tested empirically because such assumptions pertain to the 
counterfactual distribution of Y(z) given Z = 1 − z. Robins and others (e.g., see Robins, 
Rotnitzky and Scharfstein, 2000; Scharfstein, Rotnitzky and Robins, 1999) have argued that 
a data analyst should conduct sensitivity analysis to explore how inference varies as a 
function of departures from any untestable assumptions.
For instance, a departure from assumption (5) might be due to the existence of an 
unmeasured variable U associated with both treatment selection Z and the potential 
outcomes Y(z) for z = 0, 1; a variable such as U is often referred to as an unmeasured 
confounder. Under this scenario, one might postulate that Y(z) ∐ Z|U for z = 0, 1 rather than 
(5). Sensitivity analysis proceeds by examining how inference drawn about ATE varies as a 
function of the magnitude of the association of U with Z, Y(0), and Y(1). This idea has roots 
as early as Cornfield et al. (1959), who demonstrated the plausibility of a causal effect of 
cigarette smoking (Z) on lung cancer (Y) by arguing that the absence of such a relationship 
was only possible if there existed an unmeasured factor U associated with cigarette use that 
was at least as strongly associated with lung cancer as cigarette use. This idea was further 
developed by Schlesselman (1978), Rosenbaum and Rubin (1983), Lin, Psaty and Kronmal 
(1998), Hernán and Robins (1999) and VanderWeele and Arah (2011) among others.
To illustrate this approach, suppose in the AZT example above that the analyst first assumes 
(5) holds, and thus estimates the effect of AZT to be −0.48. To proceed with sensitivity 
analysis, the analyst posits the existence of an unmeasured binary variable U and assumes 
that Y(z) ∐ Z|U for z = 0, 1. Similar to VanderWeele and Arah (2011), let
Then under the assumption that Y(z) ∐ Z|U for z = 0, 1, the naive estimator converges in 
probability to E[Y(1)] − E[Y(0)] + c(1) − c(0). Thus the naive estimator is asymptotically 
unbiased if and only if c(1) = c(0). For an alternative decomposition of the asymptotic bias 
of the naive estimator, see Morgan and Winship (2007, Section 2.6.3).
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Sensitivity analysis proceeds by making varying assumptions about the unidentifiable 
associations of U with Y(0), Y(1) and Z. Under the most extreme of these assumptions, the 
bounds (2) and (3) are recovered. In particular, the upper bound in (3) is achieved when 
Pr[U = 1|Z = 1] = 0, Pr[U = 1|Z = 0] = 1, E[Y(1)|U = 1] = 1 and E[Y(0)|U = 0] = 0, meaning 
that the confounder U is perfectly negatively correlated with treatment Z and that if the 
confounder is present (U = 1), then a treated individual will die, whereas if the confounder is 
absent (U = 0), then an untreated individual will survive. The lower bound (2) is achieved 
under the opposite conditions.
In practice the extreme associations of U with Y(0), Y(1), and Z leading to the bounds might 
be considered unrealistic. Instead the analyst might consider associations only in a range 
deemed plausible by subject matter experts. In order to arrive at an accurate range, care 
should be taken in communicating the meaning of these associations and eliciting this range 
should be done in a manner that avoids data driven choices. Alternatively, the degree of 
associations required to change the sign of the effect of interest might be determined. For 
instance, suppose the analyst further assumes that E[Y(z)|U = 1] − E[Y(z)|U = 0] does not 
depend on z. This assumption will hold if the effect of Z on Y is the same if U = 0 or U = 1. 
Letting γ0 = E[Y(z)|U = 1] − E[Y(z)|U = 0] and γ1 = Pr[U = 1|Z = 1] − Pr[U = 1|Z = 0], the 
asymptotic bias of the naive estimator is then given by γ0γ1 and a bias adjusted estimator is 
found by subtracting γ0γ1 from the naive estimator. Sensitivity analysis may proceed by 
determining the values of γ0 and γ1 for which the bias adjusted estimator of the ATE will 
have the opposite sign of the naive estimator. For the AZT example, the bias adjusted 
estimator will have the opposite sign of the naive estimator if γ0γ1 < −0.48. This indicates 
that the product of (i) the difference in the mean potential outcomes between levels of the 
confounder for both treatment and control, and (ii) the difference in the prevalence of the 
unmeasured confounder between the treatment and control groups must be less than −0.48. 
Such magnitudes might be considered unlikely in the opinion of subject matter experts, in 
which case the sensitivity analysis would support the existence of a beneficial effect of AZT 
on survival among HIV+ men (ignoring sampling variability). Note the observed data 
distribution places some restrictions on the possible values of (γ0, γ1), that is, (γ0, γ1) is 
partially identifiable. For instance, if γ1 = 1 then Pr[U = 1|Z = 1] = 1 and Pr[U = 1|Z = 0] = 0 
which implies E[Y(z)|U = u] = E[Y(z)|Z = u] and, therefore, max{E[Y(1)|Z = 1] − 1, −E[Y(0)|
Z = 0]} ≤ γ0 ≤ min{E[Y(1)|Z = 1], 1 − E[Y(0)|Z = 0]}. Such considerations should be taken 
into account when determining the range of values of (γ0, γ1) in sensitivity analysis.
Because the data provide no evidence about U, VanderWeele (2008) and VanderWeele and 
Arah (2011) recommend choosing U and any simplifying assumptions based on what is 
considered plausible by relevant subject-matter experts. Such sensitivity analyses are most 
applicable when the existence of unmeasured confounders is known, but these factors could 
not be measured for logistical or other reasons. General bias formulas to be used for 
sensitivity analyses of unmeasured confounding for categorical or continuous outcomes, 
confounders and treatments can be found in VanderWeele and Arah (2011).
In other settings, there might not be any known unmeasured confounders, or it may be 
thought that there are numerous unmeasured confounders, in which cases the sensitivity 
analysis strategy described above would not be applicable or feasible. One general 
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alternative approach entails making additional untestable assumptions regarding the 
unobserved potential outcome distributions. Typically, these assumptions (or models) are 
indexed by one or more sensitivity analysis parameters conditional upon which the causal 
estimand of interest is identifiable (e.g., Scharfstein, Rotnitzky and Robins, 1999; Brumback 
et al., 2004). Sensitivity analysis then proceeds by examining how inference changes as 
assumed values of the parameters are varied over plausible ranges. Examples of such 
sensitivity analyses are given below in Sections 3.4 and 6.3.
2.5 Covariate Adjustment
Typically in observational studies baseline (pretreatment) covariates X will be collected in 
addition to Z and Y. Incorporating information from observed covariates can help sharpen 
inferences about partially identified treatment effects. For example, incorporating covariates 
will generally lead to narrower bounds (Scharfstein, Rotnitzky and Robins, 1999). This 
follows because any treatment effect compatible with the distribution of observed variables 
(X, Y, Z) must also be compatible with the distribution of (Y, Z), that is, the observable 
variables if we do not observe or choose to ignore X (Lee, 2009). Covariate adjusted bounds 
are discussed further in Section 3.3 below.
Additionally, incorporating covariates may lend plausibility to some of the bounding 
assumptions discussed in Section 2.2. For example, in the absence of randomized treatment 
assignment (4) or (5) may be dubious. Instead of (4), it might be more plausible to assume
(8)
Similarly, assumption (5) might be replaced by
(9)
that is, each potential outcome is independent of treatment selection conditional on some set 
of covariates. Assumption (9) is commonly referred to as no unmeasured confounders. 
Assumptions such as (8) or weaker inequalities similar to (6) such as
may be deemed plausible for certain levels of X, but not for others. Availability of covariates 
also allows for the consideration of new types of assumptions (e.g., see Chiburis, 2010).
To conduct covariate adjusted sensitivity analysis, departures from identifying assumptions 
such as (9) can be explored. Similar to the previous section, a departure from (9) might 
entail positing the existence of an unmeasured variable U associated with both treatment 
selection Z and the potential outcomes Y(z) for z = 0, 1. Under this scenario, one might 
postulate that Y(z) ∐ Z|{X, U} for z = 0, 1 rather than (9) and sensitivity analysis proceeds 
by examining how inference varies as a function of the magnitude of the association of U 
with Z, Y(0), and Y(1) given X. Similar to covariate adjusted bounds, smaller associations or 
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tighter regions of the values of the sensitivity parameters may be deemed plausible within 
certain levels of X, potentially yielding sharper inferences from the sensitivity analyses. 
However, as cautioned by Robins (2002), care should be taken in clearly communicating the 
meaning of such sensitivity parameters and their relationship to covariates when eliciting 
plausible ranges from subject matter experts. In some scenarios, plausible regions for 




Even if treatment is randomly assigned (e.g., as in a clinical trial), the causal estimand of 
interest may still be only partially identifiable. For example, in many studies it is often of 
interest to draw inference about treatment effects on outcomes that only exist or are 
meaningful after the occurrence of some observable intermediate variable. For instance, in 
studies where some individuals die, investigators might be interested in treatment effects 
only among individuals alive at the end of the study. Unfortunately, estimands defined by 
contrasting mean outcomes under treatment and control that simply condition on this 
observable intermediate variable do not measure a causal effect of treatment without 
additional assumptions. One approach that may be employed in this scenario entails 
principal stratification (Frangakis and Rubin, 2002). Principal stratification uses the 
potential outcomes of the intermediate post-randomization variable to define strata of 
individuals. Because these “principal strata” are not affected by treatment assignment, 
treatment effect estimands defined within principal strata have a causal interpretation and do 
not suffer from the complications of standard post-randomization adjusted estimands. The 
simple framework of principal stratification has a wide range of applications. For a recent 
discussion of the utility (and lack thereof) of principal stratification, see Pearl (2011) and 
corresponding reader reactions.
As a motivating example for this section, we consider evaluating vaccine effects on post-
infection outcomes. In vaccine studies, uninfected subjects are enrolled and followed for 
infection endpoints, and infected subjects are subsequently followed for postinfection 
outcomes such as disease severity or death due to infection with the pathogen targeted by the 
vaccine; often interest is in assessing the effect of vaccination on these post-infection 
endpoints (Hudgens and Halloran, 2006). For example, Préziosi and Halloran (2003) present 
data from a pertussis vaccine field study in Niakhar, Senegal. In this study, 3845 vaccinated 
children and 1020 unvaccinated children were followed for one year for pertussis. In the 
vaccine group, 548 children contracted pertussis, of whom 176 had severe infections; in the 
unvaccinated group 206 children contracted pertussis, of whom 129 had severe infections. In 
this setting, investigators are interested in assessing whether or not the vaccine had an effect 
on the severity of infection.
When assessing such post-infection effects, a data analyst might consider contrasts between 
study arms including all individuals under study, or, alternatively, only those who become 
infected. Though including all individuals in the study has the advantage of providing valid 
inference about the overall effect of vaccination (assuming independent treatment 
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assignment), such an approach does not distinguish vaccine effects on susceptibility to 
infection from effects on the post-infection endpoint of interest. An analysis that conditions 
on infection attempts to distinguish these effects and may be more sensitive in detecting 
post-infection vaccine effects. However, because the set of individuals who would become 
infected under control are not likely to be the same as those who would become infected if 
given the vaccine, conditioning on infection might result in selection bias. For example, 
those who would become infected under vaccine may tend to have weaker immune systems 
than those who would become infected under control, and thus may be more susceptible to 
severe infection. Because of this potential selection bias, comparisons between infected 
vaccinees and infected controls do not necessarily have causal interpretations.
3.2 Principal Effects
In this section, treatment is vaccination, with Z = 1 corresponding to vaccination and Z = 0 
corresponding to not being vaccinated. Assume that assignment to vaccine is equivalent to 
receipt of vaccine, that is, there is no noncompliance. Denote the potential infection outcome 
by S(z), where S(z) = 0 if uninfected and S(z) = 1 if infected. Here, the focus is on evaluating 
the causal effect of vaccine on Y, a post-infection outcome. For simplicity, we consider the 
case where Y is binary, indicating the presence of severe disease. If S(z) = 1, define the 
potential post-infection outcome Y(z) = 1 if the individual would have the worse (or more 
severe) post-infection outcome of interest given z, and Y(z) = 0 otherwise. If an individual’s 
potential infection outcome for treatment z is uninfected [i.e., S(z) = 0], then we adopt the 
convention that Y(z) is undefined. In other words, it does not make sense to define the 
severity of an infection in an individual who is not infected. This convention is similar to 
that employed in other settings. For instance, in the analysis of quality of life studies it might 
be assumed that quality of life metrics are not well defined in those who are not alive 
(Rubin, 2000).
Define a basic principal stratification P0 according to the joint potential infection outcomes 
SP0 = (S(0), S(1)). The four basic principal strata or response types are defined by the joint 
potential infection outcomes, (S(0), S(1)), and are composed of immune (not infected under 
both vaccine and placebo), harmed (infected under vaccine but not placebo), protected 
(infected under placebo but not vaccine), and doomed individuals (infected under both 
vaccine and placebo). Note the only stratum where both potential post-infection endpoints 
are well defined is in the doomed basic principal stratum, SP0 = (1, 1). Thus, defining a post-
infection causal vaccine effect is only possible in the doomed principal stratum SP0 = (1, 1). 
Such a causal estimand will describe the effect of vaccination on disease severity in 
individuals who would become infected whether vaccinated or not. For instance, the vaccine 
effect on disease severity may be defined by
(10)
Frangakis and Rubin call treatment effect estimands such as (10) “principal effects.”
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Assume we observe n i.i.d. copies of (Z, S, Y) denoted by (Zi, Si, Yi) for i = 1, …, n. Also 
assume that the doomed principal strata is nonempty, Pr[SP0 = (1, 1)] > 0, so that the 
principal effect in (10) is well defined. Bounds for (10) are presented below under two 
additional assumptions: independent treatment assignment, that is,
(11)
and monotone treatment response with respect to S, that is,
(12)
Assumption (11) will hold in randomized vaccine trials. Monotonicity (12) assumes that the 
vaccine does no harm at the individual level, that is, there are no individuals who would be 
infected if vaccinated but uninfected if not vaccinated. Monotonicity is equivalent to 
assuming the harmed principal stratum is empty. Note no such monotonicity assumption is 
being made regarding Y. Under (11), assumption (12) implies P(S = 1|Z = 1) ≤ P(S = 1|Z = 
0), which is testable using the observed data. For the pertussis example, the proportion 
infected in the vaccine group was less than in the unvaccinated group; thus, assuming (11), 
the data do not provide evidence against (12).
Assuming independent treatment assignment and monotonicity, (10) is partially identifiable 
from the observable data. The left term of (10) can be written
(13)
where the first equality holds under (12), the second equality under (11), and the third by 
causal consistency. On the other hand, the right term of (10) is only partially identifiable. To 
see this, note
(14)
In (14), only E[Y(0)|S(0) = 1] and Pr[S(1) = s|S(0) = 1] for s = 0, 1 are identifiable. In 
particular, E[Y(0)|S(0) = 1] = E[Y|S = 1, Z = 0] by similar reasoning to (13), and
where the first equality holds under (12) and the second under independent treatment 
assignment (and causal consistency). The other two terms in (14), namely E[Y(0)|SP0 = (1, 
1)] and E[Y(0)|SP0 = (1, 0)], are only partially identifiable. In words, infected controls are a 
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mixture of individuals in the protected and doomed principal stratum and without further 
assumptions the observed data do not identify exactly which infected controls are doomed. 
Therefore, the probability of severe disease when not vaccinated in the doomed principal 
stratum is not identified. Under (12), the data do however indicate what proportion of 
infected controls are doomed and this information provides partial identification of E[Y(0)|
SP0 = (1, 1)], and hence (10).
For fixed values of E[Y(0)|S(0) = 1] and Pr[S(1) = 1|S(0) = 1], any pair of expectations 
(E[Y(0)|SP0 = (1, 1)], E[Y(0)|SP0 = (1, 0)]) ∈ [0, 1]2 satisfying (14) will give rise to the same 
observed data distribution. Equation (14) describes a line segment with nonpositive slope 
intersecting the unit square as illustrated in Figure 1. An upper bound of E[Y(0)|SP0 = (1, 1)] 
and thus a lower bound for (10) is achieved when the line intersects the right or lower side 
of the square, that is, when either
(15)
Together (14) and (15) imply E[Y(0)|SP0 = (1, 1)] is bounded above by
(16)
Similarly, E[Y(0)|SP0 = (1, 1)] is bounded below by
(17)
Combining (17) with (13) yields the upper bound on the principal effect of interest (10) and 
combining (16) with (13) yields the lower bound. These bounds were derived by Rotnitzky 
and Jemiai (2003), Zhang and Rubin (2003) and Hudgens, Hoering and Self (2003). 
Consistent estimates of (16) and (17) can be computed by replacing E[Y(0)|S(0) = 1] with 
ΣiYiI(Si = 1, Zi = 0)/ΣiI(Si = 1, Zi = 0) and Pr[S(1) = 1|S(0) = 1] with
Returning to the pertussis vaccine study, the estimated lower and upper bounds of (10) are 
−0.57 and −0.15. These estimated bounds exclude zero, leading to the conclusion (ignoring 
sampling variability) that vaccination lowers the risk of severe pertussis in individuals who 
will become infected regardless of whether they are vaccinated.
Note if Pr[S(1) = 1|S(0) = 1] = 1, that is, the vaccine has no protective effect against 
infection, then the protected principal stratum SP0 = (1, 0) is empty and both (16) and (17) 
equal E[Y(0)|S(0) = 1] meaning that (10) is identifiable and equals E[Y|Z = 1, S = 1] − E[Y|Z 
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= 0, S = 1]. Intuitively, the lack of vaccine effect against infection eliminates the potential 
for selection bias.
As discussed in Section 2.5, incorporation of covariates can tighten bounds. For covariates X 
with finite support, one simple approach of adjusting for covariates entails determining 
bounds within strata defined by the levels of X and then taking a weighted average of the 
within strata bounds over the distribution of X. For the bounds in (16) and (17), adjustment 
for covariates will always lead to bounds that are at least as tight as bounds unadjusted for 
covariates (Lee, 2009; Long and Hudgens, 2013).
If the observed data provide evidence contrary to monotonicity (12), then bounds may be 
obtained under only (11). Without monotonicity (12), the proportion of infected controls that 
are in the doomed principal stratum is no longer identified but may be bounded in order to 
arrive at bounds for E[Y(0)|SP0 = (1, 1)]. In addition, the harmed principal stratum defined 
by SP0 = (0, 1) is no longer empty and thus E[Y(1)|SP0 = (1, 1)] is no longer identifiable 
from the observed data and may also be bounded in a similar fashion to E[Y(0)|SP0 = (1, 1)]. 
Details regarding these bounds without the monotonicity assumption may be found in Zhang 
and Rubin (2003) and Grilli and Mealli (2008).
3.4 Sensitivity Analysis
The bounds (16) and (17) are useful in bounding the vaccine effect on Y in the doomed 
stratum. However, these bounds may be rather extreme. An alternative approach is to make 
an untestable assumption that identifies the post-infection vaccine effect on Y and then 
consider how sensitive the resulting inference is to departures from this assumption. For 
instance, assuming
(18)
identifies (10). Hudgens and Halloran (2006) refer to this as the no selection model. To 
examine how inference varies according to departures from (18), following Scharfstein, 
Rotnitzky and Robins (1999), and Robins, Rotnitzky and Scharfstein (2000), consider the 
following sensitivity parameter:
(19)
In words, exp(γ) compares the odds of severe disease when not vaccinated in the doomed 
versus the protected principal stratum. Assuming (18) corresponds to γ = 0. A sensitivity 
analysis entails examining how inference about (10) varies as γ becomes farther from 0. For 
any fixed value of γ, (10) is identified (see Figure 1) and can be consistently estimated by 
maximum likelihood estimation without any additional assumptions (Gilbert, Bosch and 
Hudgens, 2003). The lower and upper bounds (17) and (16) are obtained by letting γ → ∞ 
and γ → −∞. To see this, note that as γ → ∞ (19) implies in the limit that either
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which is equivalent to (15). Sensitivity analysis can be conducted by letting γ range over a 
set of values Γ.
Tighter bounds can be achieved by placing restrictions on Γ, perhaps based on prior beliefs 
about γ elicited from subject matter experts. For example, Shepherd, Gilbert and Mehrotra 
(2007) surveyed 10 recognized HIV experts in order to elicit a plausible range for a 
sensitivity parameter representing a departure from the assumption of no selection bias 
between vaccinated and unvaccinated individuals who acquired HIV during an HIV vaccine 
trial. Included in this survey was the analysis approach, a brief explanation of the potential 
for selection bias, the definition of the sensitivity parameter being employed, examples of 
the implications of certain sensitivity parameter values on selection bias and possible 
justification for believing certain values of the sensitivity parameter. The expert responses to 
the survey were fairly consistent and several written justifications for the respondents’ 
chosen ranges indicated a high level of understanding of both the counterfactual nature of 
the sensitivity parameter and the need to account for selection bias.
4. RANDOMIZED STUDIES WITH PARTIAL COMPLIANCE
4.1 Global Average Treatment Effect
In a placebo controlled randomized trial where (5) holds but there is non-compliance (i.e., 
individuals are randomly assigned to treatment or control but they do not necessarily adhere 
or comply with their assigned treatment), the naive estimator is a consistent estimator of the 
average effect of treatment assignment. However, in this case parameters other than the 
effect of treatment assignment may be of interest. As in the last section, a principal effect 
may be defined using compliance as the intermediate post-randomization variable over 
which to define principal strata; namely the principal strata would consist of individuals who 
would comply with their randomization assignment if assigned treatment or control or 
“compliers,” individuals who would always take treatment regardless of randomization or 
“always takers,” individuals who never take treatment “never takers” and individuals who 
take treatment only if assigned control or “defiers.” A principal effect of interest might be 
the effect of treatment in the complier principal stratum (Imbens and Angrist, 1994; Angrist, 
Imbens and Rubin, 1996), in which case bounds and sensitivity analyses similar to those in 
Section 3 are applicable. However, as several authors including Robins (1989) and Robins 
and Greenland (1996) have pointed out, such principal effects may not be of ultimate public 
health interest because they only apply to the subpopulation of compliers in clinical trials, 
which may differ from the population that elect to take treatment once licensed. For 
example, once efficacy is proved, a larger subpopulation of people may be willing to take 
the treatment. Effects defined on the subpopulation of compliers are also of limited decision-
making utility because individual principal stratum membership is generally unknown prior 
to treatment assignment (Joffe, 2011).
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Robins and Greenland (1996) suggested that in settings where the trial population could be 
persuaded to take the treatment once licensed, a more relevant public health estimand is the 
global average treatment effect, defined as the average effect of actually taking treatment 
versus not taking treatment given treatment assignment z. This causal estimand is similar to 
the average treatment effect defined in Section 2, but requires generalizing the potential 
outcome definitions used previously to include separate potential outcomes for each of the 
four combinations of treatment assignment and actual treatment received. For further 
discussion regarding causal models in presence of noncompliance, see Chickering and Pearl 
(1996) and Dawid (2003) among others.
Suppose we observe data from a clinical trial where each individual is randomly assigned to 
treatment or control. Let Z indicate treatment assignment where Z = 1 denotes treatment and 
Z = 0 denotes control. Suppose individuals do not necessarily comply with their 
randomization assignment and let S be a variable indicating whether or not treatment was 
actually taken, where S = 1 denotes treatment was taken and S = 0 otherwise. Thus, an 
individual is compliant with their randomization assignment if S = Z. Let Y be a binary 
outcome of interest. Denote the potential treatment taken by S(z) for z = 0, 1, where S(z) = 1 
indicates taking treatment when assigned z and S(z) = 0 denotes not taking treatment when 
assigned z. Let Y(z, s) denote the potential outcome if an individual is assigned treatment z 
but actually takes treatment s. Conceiving of these potential outcomes depends on a 
supposition that trial participants who did not comply in the trial could be persuaded to take 
the treatment under other circumstances. Given this supposition, the global average 
treatment effect for each treatment assignment z = 1 and z = 0 is defined as GATEz = E[Y(z, 
1) − Y(z, 0)]. For instance, GATE1 is the difference in the average outcomes under the 
counterfactual scenario everyone was assigned vaccine and did comply versus the 
counterfactual scenario everyone was assigned vaccine but did not comply.
Bounds for GATEz are given below under three assumptions: independent treatment 
assignment
(20)
monotonicity with respect to S
(21)
and the exclusion restriction
(22)
Assumption (22) indicates treatment assignment has no effect when the actual treatment 
taken is held fixed. Under (22), GATE0 = GATE1 which we denote by GATE. In this case 
each individual has two potential outcomes according to s = 0 and s = 1 [which could be 
denoted by Y(s) = Y(0, s) = Y(1, s) for s = 0, 1] and GATE is equivalent to the ATE 
discussed in Section 2 with z replaced by s. Robins (1989) derived bounds for GATE under 
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several different combinations of (20)–(22) as well as some additional assumptions such as 
monotonicity with respect to S, that is, Y(z, 1) ≥ Y(z, 0) for z = 0, 1. Manski (1990) 





Balke and Pearl (1997) derived sharp bounds for GATE under a variety of assumptions, 
including (20)–(22), by recognizing that the derivation of the bounds is equivalent to a linear 
programming optimization problem. To see that bounds can be formulated as a linear 
programming optimization problem, first note that GATE can be expressed as a linear 
combination of probabilities of the joint distribution of L = (Y(0, 0), Y(0, 1), Y(1, 0), Y(1, 1), 
S(0), S(1))
(25)
where  is the set of possible realizations of L where Y(0, s) = Y(1, s) = 1 for s = 0, 1. Under 
independent treatment assignment, there exists a linear transformation between the 
probabilities in the joint distribution of L and the probabilities in the conditional distribution 
of the observable random variables Y and S given Z, namely
(26)
where  is the set of possible realizations of L where S(z) = s and Y(z, s) = y for z, y, s = 0, 
1. To find the sharp bounds, the objective function (25) is minimized (or maximized) subject 
to the constraints (26), Pr[L = l] ≥ 0 for every l ∈ , and  Pr[L = l] = 1 where  is the set 
of all possible realizations of L assuming (21) and (22). Optimization may be accomplished 
using the simplex algorithm and the dimension of this problem permits obtaining a closed 
form solution involving probabilities of the observed data distribution (Balke and Pearl, 
1993), namely (23) and (24).
If in addition to assumptions (20) and (22), it is assumed that
(27)
for s, z = 0, 1 then GATE is identified and equals
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(Hernán and Robins, 2006). For s = 0 assumption (27) is known as a no current treatment 
interaction assumption (Robins, 1994), and expression (28) is known as the instrumental 
variables estimand (Imbens and Angrist, 1994; Angrist, Imbens and Rubin, 1996). 
Sensitivity analyses may be conducted by defining sensitivity parameters representing 
departures from (20), (22) or (27) and then examining how inference about GATE varies as 
values of these parameters change. For instance, Robins, Rotnitzky and Scharfstein (2000) 
define current treatment interaction functions which represent a departure from (27) for s = 
0.
4.2 Cholestyramine Example
To illustrate the GATE, we consider data presented in Pearl (2009, Section 8.2.6) on 337 
subjects who participated in a randomized trial to assess the effect of cholestyramine on 
cholesterol reduction. Let Z = 1 denote assignment to cholestyramine and Z = 0 assignment 
to placebo. Let S = 1 if cholestyramine was actually taken by the participant and S = 0 
otherwise. Let Y = 1 if the participant had a response and Y = 0 otherwise, where response is 
defined as reduction in the level of cholesterol by 28 units or more. Pearl reported the 
following observed proportions:
No participants assigned placebo actually took cholestyramine, suggesting the monotonicity 
assumption (21) is reasonable. On the other hand, 38.8% of individuals assigned treatment 
did not actually take cholestyramine.
From (23) and (24), the bounds on GATE assuming (21), (20) and (22) are estimated to be 
−1 + max{0.000, 0.473} + max{0.919, 0.315} = 0.392 and 1 − max{0, 0.139} − max{0.081, 
0.073} = 0.780. The positive sign of the estimated bounds indicates the treatment is 
beneficial. Pearl interprets the estimated bounds as follows: “although 38.8% of the subjects 
deviated from their treatment protocol, the experimenter can categorically state that, when 
applied uniformly to the population, the treatment is guaranteed to increase by at least 
39.2% the probability of reducing the level of cholesterol by 28 points or more.” Such an 
interpretation does not account for sampling variability, the topic of Section 7.
Richardson et al. Page 17























5.1 Natural Direct and Indirect Effects
As demonstrated in Sections 3 and 4, independent treatment assignment does not guarantee 
that the causal estimand of interest will be identifiable. Another setting where this occurs is 
in mediation analysis, where researchers are interested in whether or not the effect of a 
treatment is mediated by some intermediate variable. Even in studies where treatment is 
assigned randomly and there is perfect compliance, confounding may exist between the 
intermediate variable and the outcome of interest such that effects describing the mediated 
relationships will not in general be identifiable. Thus, bounds and sensitivity analysis may 
be helpful in drawing inference.
To illustrate, let Y be an observed binary outcome of interest, and S a binary intermediate 
variable observed some time between treatment assignment Z and the observation of Y. The 
goal is to assess whether and to what extent the effect of Z on Y is mediated by or through S. 
Denote the potential outcome of the intermediate variable under treatment z by S(z) for z = 0, 
1 such that S = S(Z), and the potential outcomes under treatment z and intermediate s as Y(z, 
s) such that Y = Y(Z, S(Z)). Here, as in the previous section, it is assumed that both Z and S 
can be set to particular fixed values, such that there are four potential outcomes for Y per 
individual. Unless otherwise specified, independent treatment assignment (20) will be 
assumed throughout this section.
Define the total effect of treatment to be E[Y(1, S(1)) − Y(0, S(0))], which is equivalent to 
the ATE defined in Section 2.1. The total effect of treatment can be decomposed in the 
following way:
(29)
for z = 0,1 and z′ = 1 − z. The right-hand side of (29) decomposes the total effect into the 
sum of two separate effects. The first expectation on the right-hand side of (29) is the natural 
direct effect for treatment z, NDEz = E[Y(1, S(z)) − Y(0, S(z))] (Robins and Greenland, 1992; 
Pearl, 2001; Robins, 2003; Kaufman, Kaufman and MacLehose, 2009; Robins and 
Richardson, 2010). The natural direct effect is the average effect of the treatment on the 
outcome when the intermediate variable is set to the potential value that would occur under 
treatment assignment z. The second expectation on the right-hand side of (29) is the natural 
indirect effect, NIEz = E[Y(z, S(1)) − Y(z, S(0))] (Pearl, 2001; Robins, 2003; Imai, Keele and 
Yamamoto, 2010). The natural indirect effect is the difference in the average outcomes 
when treatment is set to z and the intermediate variable is set to the value that would have 
occurred under treatment compared to if the intermediate variable were set to the value that 
would have occurred under control.
Though the total effect is identifiable assuming (20), the natural direct and indirect effects 
are not identifiable since they entail E[Y(z, S(1 − z))] which depends on unobserved 
counterfactual distributions. Sjölander (2009) derived bounds for the natural direct effects 
assuming only independent treatment assignment (20) using the linear programming 
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technique of Balke and Pearl (1997). This results in the following sharp lower and upper 
bounds for NDE0 and NDE1:
(30)
(31)
where pys·z = Pr(Y = y, S = s|Z = z). These bounds may exclude 0, indicating a natural direct 
effect of treatment z when the intermediate variable is set to S(z) (ignoring sampling 
variability). There are instances where the bounds in (30) and (31) may collapse to a single 
point, for example, if p10·0 = p10·1 = 1. Using (29), bounds for NIE0 and NIE1 can be 
obtained by subtracting the bounds for NDE1 and NDE0 from the total effect, which is 
identified under (20) and equal to (p11·1 + p10·1) − (p10·0 − p11·0).
Just as in Sections 2–4, monotonicity assumptions can be made to tighten the above bounds. 
For instance, if
are assumed, then Pr[L = l] = 0 for all l such that (i) S(0) = 1 and S(1) = 0, (ii) Y(0, s) = 1 and 
Y(1, s) = 0 for s = 0 or 1 or (iii) Y(z, 0) = 1 and Y(z, 1) = 0 for s = 0 or 1, which restricts the 
feasible region of the linear programming problem. The resulting sharp bounds for the 
natural direct effect are
(32)
(Sjölander, 2009). The bounds (32) are always at least as narrow as (30) and (31). 
Interestingly these narrower bounds do not depend on z. The bounds in (32) may also 
collapse to a single point, for example, if p10·0 = p10·1 and p01·0 − p01·1 = p11·1 − p11·0.
The natural direct effect provides insight into whether or not treatment yields additional 
benefit on the outcome of interest when the influence of treatment on the intermediate 
variable is eliminated. However, researchers might also be interested in what benefit is 
provided by treatment if the effect of the intermediate variable on the outcome is eliminated 
or held constant. This question suggests a different causal estimand known as the controlled 
direct effect. Bounds for the controlled direct effect can be found in Pearl (2001), Cai et al. 
(2008), Sjölander (2009) and VanderWeele (2011a).
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As in other settings where the effect of interest is not identifiable, sensitivity analysis in the 
mediation setting may be conducted by making untestable assumptions that identify the 
direct or indirect effects. Then sensitivity of inference to departures from these assumptions 
can be examined. For example, if (20) holds, then the natural direct and indirect effects are 
identified under the following additional assumptions
(33)
(34)
(Pearl, 2001; VanderWeele, 2010). Assumption (33) would be valid if subjects were 
randomly assigned S within different levels of treatment assignment Z. In settings where S is 
not randomly assigned, (33) might be considered plausible if it is believed that conditional 
on Z there are no variables which confound the mediator–outcome relationship. Both 
assumptions (33) and (34) will not hold in general if Z has an effect on some other 
intermediate variable, say R, which in turn has an effect on both S and Y. Thus, (33) and (34) 
may fail unless the mediator S occurs shortly after treatment Z. Under assumptions (20), (33) 
and (34),
and
Because assumptions (33) and (34) cannot be empirically tested, sensitivity analysis should 
be conducted. Similar to Section 2.4, sensitivity analysis might proceed by positing the 
existence of an unmeasured confounding variable U associated with the potential mediator 
values S(z) and the potential outcomes Y(z, s) for z, s = 0, 1. Assumption (33) would then 
replaced by Y(z, s) ∐ S|{Z, U} and (34) by Y(z, s) ∐ S(z′)|U for s, z, z′ = 0, 1. Sensitivity 
analysis would then proceed by exploring how inference about the natural direct and indirect 
effects changes as the magnitude of the associations of U with S(z) and Y(s, z′) for z, z′, s = 
0, 1 vary. For further details regarding bounds and sensitivity analysis in mediation analysis, 
see Imai, Keele and Yamamoto (2010), VanderWeele (2010) and Hafeman (2011).
6. LONGITUDINAL TREATMENT
6.1 Background
In Sections 2–5, treatment is assumed to remain fixed across follow up time and outcomes 
are one-dimensional. However, frequently researchers are interested in assessing causal 
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effects comparing longitudinal outcomes for patients on different treatment regimens where 
treatment may vary in time. As the number of times at which an individual may receive 
treatment increases, the number of possible treatment regimens increases exponentially. 
Because each treatment regimen corresponds to a separate potential (longitudinal) outcome 
and only one potential outcome is ever observed, the fraction of potential outcomes that are 
unobserved quickly grows close to one as the number of possible treatment times increases. 
As in other settings, unless treatment regimens are randomly assigned, regimen effects will 
not be identifiable without additional assumptions. In the longitudinal setting, bounds will 
typically be largely uninformative because of the high proportion of unobserved potential 
outcomes. Therefore, analyses usually proceed by invoking modeling assumptions that 
render treatment effects identifiable and then conducting sensitivity analysis corresponding 
to key untestable modeling assumptions.
Models for potential outcomes as functions of covariates (such as treatment) and possibly 
other potential outcomes are often referred to as structural models. For longitudinal potential 
outcomes and treatments, popular models include structural nested models and marginal 
structural models (Robins, Rotnitzky and Scharfstein, 2000; Robins, 1999; van der Laan and 
Robins, 2003; Brumback et al., 2004). In Section 6.2 below, we consider a marginal 
structural model where the treatment effect is identified assuming conditionally independent 
treatment assignment. Sensitivity analyses exploring departures from this assumption are 
then considered in Section 6.3.
6.2 Marginal Structural Model
Consider a study where individuals possibly receive treatment at τ fixed time points (i.e., 
study visits). In general let Ā(t) = (A(0), …, A(t)) represent the history of variable A up to 
time t and Ā be the entire history of variable A such that Ā = Ā(τ). Let z(t) = 1 indicate 
treatment at visit t, and z(t) = 0 otherwise such that z̄ represents a treatment regimen for 
visits 0, …, τ. Denote the observed treatment regimen up to time t as Z̄(t). Let Y be some 
outcome of interest that may be categorical or continuous, and denote the potential outcome 
of Y at visit t for regimen z̄ by Y(z̄, t) and the observed outcome by Y(t). Let X̄(t) denote the 
history of some set of time varying covariates up to time t, where X(0) denotes the baseline 
covariates. Assume for simplicity there is no loss to follow-up or noncompliance such that 
we observe n i.i.d. copies of (Z̄, Ȳ, X̄).
Consider the following marginal structural model of the mean potential outcome were the 
entire population to follow regimen z̄ up to time t:
(35)
for t ∈ {1, …, τ}, where  and g(·) is an appropriate link function. 
The causal estimand of interest is β1, the regression coefficient for cum[z̄(t − 1)], which is 
the effect of having received treatment at one additional visit prior to time t conditional on 
baseline covariates X(0). Because (35) involves counterfactual outcome distributions, β1 is 
not identifiable without additional assumptions. One additional assumption is conditionally 
independent treatment assignment
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(Robins, Rotnitzky and Scharfstein, 2000; Robins, 1999; Brumback et al., 2004). This 
assumption is true if the potential outcome at visit t under treatment regimen z̄ is 
independent of the observed treatment at visit k given the history of treatment up to visit k − 
1 and the covariate history up to visit k. Assuming both a correctly specified model (35) and 
conditionally independent treatment assignment (36), fitting the following model to the 
observed data:
using generalized estimating equations with an independent working correlation matrix and 
time varying inverse probability of treatment weights (IPTW) yields an estimator η̂1 that is 
consistent for β1 (Tchetgen Tchetgen et al., 2012a, 2012b).
6.3 Sensitivity Analysis
If assumption (36) does not hold, then the IPTW estimator η̂1 is not necessarily consistent. 
Because (36) is not testable from the observed data, sensitivity analysis might be considered 
to assess robustness of inference to departures from (36). Following Robins (1999) and 
Brumback et al. (2004), let
for t > k and z̄ such that Pr[Z(k) = z(k)|Z̄(k − 1) = z̄(k − 1)] is bounded away from 0 and 1. 
The function c quantifies departures from the conditional independent treatment assignment 
assumption (36) at each visit t > k, where c(t, k, z̄(t − 1), x̄(k)) = 0 for all z̄ and t > k if (36) 
holds. For the identity link, a bias adjusted estimator of the causal effect β1 may be obtained 
by recalculating the IPTW estimator with the observed outcome Y(t) replaced by Yγ(t) = Y(t) 
− b(Z̄(t − 1), X̄(t − 1)) where
and f[z(k)|z̄(k − 1), x̄(k)] = P̂r[Z(k) = z(k)|Z̄(k − 1) = z̄(k − 1), X̄(k) = x̄(k)] is an estimate of the 
conditional probability of the observed treatment based on some fitted parametric model 
(Brumback et al., 2004). Provided this parametric model and c are both correctly specified, 
this bias adjusted estimator, say η̃1, is consistent for β1. Sensitivity analysis proceeds by 
examining how η̃1 changes when varying sensitivity parameters in c(t, k, z̄(t − 1), x̄(k)).
Because c(t, k, z̄(t − 1), x̄(k)) is not identifiable from the observable data, Robins (1999) 
recommends choosing a particular c that is easily explainable to subject matter experts to 
facilitate eliciting plausible ranges of the sensitivity parameters. As an example of a 
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particular c, Brumback et al. (2004) suggest c(t, k, z̄(t − 1), x̄(k)) = γ{2z(k) − 1} where γ is an 
unidentifiable sensitivity analysis parameter. Note that c(t, k, z̄(t − 1), x̄(k)) = γ for z(k) = 1 
and c(t, k, z̄(t − 1), x̄(k)) = −γ for z(k) = 0. Thus, γ > 0 (γ < 0) corresponds to subjects 
receiving treatment at time k having greater (smaller) mean potential outcomes at future visit 
t than those who did not receive treatment at visit k. When γ = 0, Y(t) = Yγ(t) and therefore 
η̃1 = η̂1. The function c might depend on the baseline covariates X(0) or the time-varying 
covariates X̄(k). In this case, as in Section 2.5, care should be taken in clearly 
communicating the sensitivity parameters’ relationship to these covariates when eliciting 
plausible ranges from subject matter experts. Another consideration when choosing a 
function c is whether it will allow for the sharp null of no treatment effect, that is, for all 
individuals Y(z̄, t) = Y(z̄′, t) for all z̄, z̄′, t. The example function c presented above allows for 
the sharp null. See Brumback et al. (2004) for other example c functions and further 
discussion of sensitivity analysis for marginal structural models.
7. IGNORANCE AND UNCERTAINTY REGIONS
Treatment effect bounds describe ignorance due to partial identifiability but do not account 
for uncertainty due to sampling error. This section discusses some methods to appropriately 
quantify uncertainty due to sampling variability when drawing inference about partially 
identifiable treatment effects. Over the past decade, a growing body of research, especially 
in econometrics, has considered inference of partially identifiable parameters. The approach 
presented below draws largely upon Vansteelandt et al. (2006), who considered methods for 
quantifying uncertainty in the general setting where missing data causes partial 
identifiability. As questions about treatment (or causal) effects can be viewed as missing 
data problems, the approach of Vansteelandt et al. generally applies (under certain 
assumptions) to the type of problems considered throughout this paper. This approach builds 
on earlier work by Robins (1997) and others.
7.1 Ignorance Regions
Let L be a vector containing the potential outcomes for an individual, let O denote the 
observed data vector, and let R be a vector containing indicator variables denoting whether 
the corresponding component of L is observed. For example, L = (Y(1), Y(0)), O = (Z, Y), 
and R = (Z, (1 − Z)) for the scenario described in Section 2 and L = (Y(1), Y(0), S(1), S(0)), O 
= (Z, Y, S) and R = (Z, (1 − Z), Z, (1 − Z)) for the scenario described in Section 3. Denote the 
distribution of (L, R) by f(L, R) and let f(L) = ∫ f(L, R)dR. The goal is to draw inference 
about a parameter vector β which is a functional of the distribution of potential outcomes L; 
this is sometimes made explicit by writing β = β{f(L)}. Denote the true distribution of (L, R) 
by f0(L, R) and the true value of β by β0 = β{f0(L)}. For example, β0 = E[Y(1) − Y(0)] for the 
scenario described in Section 2 and β0 = E[Y(1) − Y(0)|SP0 = (1, 1)] for the scenario 
described in Section 3. Denote the true observed data distribution by f0(O) = ∫ f0(L, R) 
dL(1 − R) where L(1 − r) denotes the missing part of L when R = r (i.e., the unobserved 
potential outcomes). The challenge in drawing inference about β0 is that there may be 
multiple full data distributions f(L, R) that marginalize to the true observed data distribution, 
that is, f0(O) = ∫ f(L, R)dL(1 − R) for some f ≠ f0. When this occurs, β may be only partially 
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identifiable from O, in which case bounds can be derived for β0 as illustrated in the sections 
above.
The set of values of β{f(L)} such that f(L, R) marginalizes to the true observed data 
distribution is sometimes called the ignorance region or the identified set. These ignorance 
regions or intervals are distinct from traditional confidence intervals in that as the sample 
size tends to infinity these intervals will not shrink to a single point when β is partially 
identifiable. The ignorance region for β can be defined formally as follows. Following 
Robins (1997), define a class (γ) of full data laws indexed by some sensitivity parameter 
vector γ to be nonparametrically identified if for each observed data law f(O) there exists a 
unique law f(L, R; γ) ∈ (γ) such that f(O) = ∫ f(L, R; γ)dL(1 − R). In other words, the class 
(γ) contains a unique distribution that marginalizes to each possible observed data 
distribution. For example, for the sensitivity analysis approach in Section 3.4, Hudgens and 
Halloran (2006, §4.3.3) defined a class of full data laws indexed by γ given in (19) that is 
nonparametrically identified. The ignorance region for β is formally defined to be
(37)
where Γ is the set of all possible values of γ under whatever set of assumptions is being 
invoked and (Γ) = ⋃γ ∈ Γ (γ). Assume (Γ) contains the true full data distribution, that 
is, f0(L, R) = f(L, R, γ0) for some γ0 ∈ Γ. [For considerations when (Γ) does not contain 
the true full data distribution, see Todem, Fine and Peng (2010).] Because (γ) is 
nonparametrically identified, for each γ ∈ Γ there is a single β(γ) = β{∫ f(L, R; γ)dR)} in the 
ignorance region (37). If (Γ) includes all possible full data distributions that marginalize 
to any possible observed data distribution, then the ignorance region will contain the bounds.
In practice, the ignorance region will be unknown because it depends on the unknown true 
observed data distribution f0(O). For γ fixed, β(γ) is identifiable from the observed data and 
the ignorance region can be estimated by estimating β(γ) for each value of γ ∈ Γ, denoted by 
β̂(γ). The resulting estimator of irf0(β, Γ) is then {β
̂(γ) : γ ∈ Γ}. For scalar β(γ), let β̂l = 
infγ ∈ Γ{β̂(γ)} and β̂u = supγ ∈ Γ{β̂(γ)} such that the estimated ignorance region is contained 
in the interval [β̂l, β̂u].
7.2 Uncertainty Regions
Estimated ignorance regions convey ignorance due to partial identifiability and do not 
reflect sampling variability in the estimates. Indeed much of the literature on bounds and 
sensitivity analysis of treatment effects tends to report estimated ignorance regions and 
either ignores sampling variability or employs ad-hoc inferential approaches such as 
pointwise confidence intervals conditional on each value of the unidentifiable sensitivity 
parameter. More recent developments have provided a formal framework for conducting 
inference in partial identifiability settings (Imbens and Manski, 2004; Vansteelandt et al., 
2006; Romano and Shaikh, 2008; Bugni, 2010; Todem, Fine and Peng, 2010). The main 
focus in this research has been the construction of confidence regions for either the 
parameter β0 or the ignorance region irf0(β0, Γ).
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Following Vansteelandt et al. (2006), a (1 − α) pointwise uncertainty region for β0 is defined 
to be a region URp(β, Γ) such that
where Prf0 {·} denotes probability under f0(O). That is, URp(β, Γ) contains β(γ) with at least 
probability 1 − α for all γ ∈ Γ. In particular, assuming γ0 ∈ Γ, then URp(β, Γ) will contain β0 
= β(γ0) with at least probability 1 − α.
An appealing aspect of pointwise uncertainty regions is that they retain the usual duality 
between confidence intervals and hypothesis testing. Namely, one can test the null 
hypothesis H0 : β0 = βc versus Ha : β0 ≠ βc for some specific βc at the α significance level by 
rejecting H0 when the (1 − α) pointwise uncertainty region URp(β, Γ) excludes βc. This is 
easily shown by noting for βc = β(γ0)
where the last inequality follows because URp(β, Γ) is a (1 − α) pointwise uncertainty 
region.
Various methods under different assumptions have been proposed for constructing pointwise 
uncertainty regions. Imbens and Manski (2004) and Vansteelandt et al. (2006) proposed a 
simple method for constructing pointwise uncertainty regions for a scalar β with ignorance 
region [βl, βu]. Let γl, γu ∈ Γ be the values of the sensitivity parameter such that βl = β(γl) 
and βu = β(γu). Assume
(38)
(39)
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Φ(·) denotes the cumulative distribution function of a standard normal variate, and σ̂l and σ̂u 
are consistent estimators of σl and σu, respectively (Imbens and Manski, 2004; Vansteelandt 
et al., 2006). Note if βû − β̂l > 0 and n is large such that the left-hand side of (41) is 
approximately equal to 1 − Φ(−cα), then cα ≈ z1 − α, the (1 − α) quantile of a standard 
normal distribution. In contrast, if βû = β̂l, then cα = z1 − α/2.
In addition to the pointwise uncertainty region, Horowitz and Manski (2000) and 
Vansteelandt et al. (2006) define a (1 − α) strong uncertainty region for β0 to be a region 
URs(β, Γ) such that
that is, URs(β, Γ) contains the entire ignorance region with probability at least 1 − α. 
Whereas the pointwise uncertainty region can be viewed as a confidence region for the 
partially identifiable target parameter β0, the strong uncertainty region is a confidence region 
for the ignorance region irf0(β, Γ). Clearly, any strong uncertainty region will also be a 
(conservative) pointwise uncertainty region as β0 ∈ irf0(β, Γ). Under assumptions (38) and 
(39), an asymptotic (1 − α) strong uncertainty interval for scalar β0 is simply
(42)
Note that (42) is equivalent to the union of all pointwise (1 − α) confidence intervals for β(γ) 
under (γ) over all γ ∈ Γ, which is a simple approach often employed when reporting 
sensitivity analysis. Because strong uncertainty intervals are necessarily pointwise intervals, 
this simple approach is also a valid method for computing pointwise intervals, although 
intervals based on (40) will always be as or more narrow.
The two key assumptions (38) and (39) may not hold in general. For example, (38) may not 
hold for all possible observed data distributions, particularly for extreme values of γl or γu. 
Assumption (39) may not hold if different observed data distributions place different 
constraints on the possible range of γ or if Γ is chosen by the data analyst on the basis of the 
observed data. If (38) or (39) does not hold, alternative inferential methods are needed (e.g., 
see Vansteelandt and Goetghebeur, 2001; Horowitz and Manski, 2006; Chernozhukov, 
Hong and Tamer, 2007; Romano and Shaikh, 2008; Stoye, 2009; Todem, Fine and Peng, 
2010; Bugni, 2010).
A third approach to quantifying uncertainty due to sampling variability is to consider β(·) as 
function of γ and construct a (1 − α) simultaneous confidence band for the function β(·). 
That is, a random function CB(·) is found such that
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It follows immediately that ⋃γ ∈ Γ CB(γ) is a strong uncertainty region (and thus a pointwise 
uncertainty region as well). Todem, Fine and Peng (2010) suggest a bootstrap approach to 
constructing confidence bands.
Whether pointwise uncertainty regions, strong uncertainty regions, or confidence bands are 
preferred will be context specific. Typically, it is of interest to draw inference about a single 
target parameter and not the entire ignorance region. Thus, in general pointwise uncertainty 
regions may have greater utility than strong uncertainty regions. Because strong uncertainty 
regions are necessarily conservative pointwise uncertainty regions, the strong regions can be 
useful in settings where determining a pointwise region is more difficult. Additionally, in 
some settings it may be of interest to assess whether β is nonzero, for example, if β denotes 
the effect of treatment. In these settings, computing a confidence band CB(·) has the 
advantage of providing the subset of Γ where the null hypothesis β(γ) = 0 can be rejected. 
This is especially appealing if γ is scalar, in which case a confidence band (as in Figure 3 of 
Todem, Fine and Peng, 2010) provides a simple approach to reporting sensitivity analysis 
results. On the other hand, if γ is multidimensional, visualizing confidence bands can be 
difficult and instead reporting the (pointwise or strong) uncertainty region may be more 
practical.
7.3 Data Example
Returning to the pertussis vaccine study described in Section 3, an analysis that ignores the 
potential for selection bias might entail computing a naive estimator (the difference in 
empirical means of Y between the vaccinated and unvaccinated amongst those infected) 
along with a 95% Wald confidence interval, which would be −0.31 (95% CI −0.38, −0.23). 
If the sensitivity analysis approach in Section 3.4 is applied, the parameter of interest β(γ) = 
E[Y(1) − Y(0)|SP0 = (1, 1)] is identified for fixed values of the sensitivity analysis parameter 
γ given in (19). For fixed γ, E[Y(0)|SP0 = (1, 1)] is determined by the intersection of the 
negative sloped line (14) and the curve (19), which is illustrated in Figure 1 for the pertussis 
data. Because E[Y(0)|SP0 = (1, 1)] increases with γ, β(γ) is a monotonically decreasing 
function of γ. Therefore γl and γu equal the maximum and minimum values of Γ regardless 
of the observed data law, indicating (39) holds provided that Γ is chosen by the analyst 
independent of the observed data. For γ fixed and finite, β(γ) can be estimated via 
nonparametric maximum likelihood (i.e., without any additional assumptions). This 
estimator will be consistent and asymptotically normal under standard regularity conditions 
if Pr[S(0) > S(1)] > 0 (i.e., the vaccine has a protective effect against infection). For γ = ±∞ 
and Pr[S(0) > S(1)] > 0, Lee (2009) proved that the estimators of the bounds similar to those 
given in Section 3.3 are consistent and asymptotically normal for a continuous outcome Y. 
The limiting distribution of the estimator of the upper bound (γ = −∞) for a binary outcome 
will be normal if in addition
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and similarly the estimator of the lower bound (γ = ∞) will be asymptotically normal if in 
addition
(44)
Likelihood ratio tests for the null hypotheses that (43) and (44) do not hold yield p-values p 
< 10−4 and p = 0.18, respectively, indicating strong evidence that (43) holds and equivocal 
evidence regarding (44). Assuming (43) and (44) both hold implies (38), such that (40) and 
(42) can be used to construct (1 − α) pointwise and strong uncertainty intervals for β0. 
Estimated ignorance and uncertainty intervals of β0 for different choices of Γ are given in 
Table 1 and Figure 2, with standard error estimates obtained using the observed information. 
Even for Γ = (−∞, ∞) both the pointwise and strong uncertainty intervals exclude zero, 
indicating a significant effect of vaccination. In particular, with 95% confidence we can 
conclude the vaccine decreased the risk of severe disease among individuals who would 
have become infected regardless of vaccination.
8. DISCUSSION
This paper considers conducting inference about the effect of a treatment (or exposure) on 
an outcome of interest. Unless treatment is randomly assigned and there is perfect 
compliance, the effect of treatment may be only partially identifiable from the observable 
data. Through the five settings in Sections 2–6, we discussed two approaches often 
employed to address partial identifiability: (i) bounding the treatment effect under minimal 
assumptions, or (ii) invoking additional untestable assumptions that render the treatment 
effect identifiable and then conducting sensitivity analysis to assess how inference about the 
treatment effect changes as the untestable assumptions are varied. Incorporating uncertainty 
due to sampling variability was discussed in Section 7, and throughout large-sample 
frequentist methods were considered. Analogous Bayesian approaches to partial 
identification (Gustafson, 2010; Moon and Schorfheide, 2012; Richardson, Evans and 
Robins, 2011) and sensitivity analysis (McCandless, Gustafson and Levy, 2007; Gustafson 
et al., 2010) have also been developed.
Determining treatment effect bounds is essentially a constrained optimization problem, 
where the constraints are determined by the relationship between the distributions of the 
observable random variables and of the potential outcomes under whichever assumptions are 
being made. In simple cases, such as in Section 2.1, bounds can easily be derived from first 
principles and may have simple closed forms; in more complicated settings, such as in 
Section 4, bounds may be determined using linear programming or other optimization 
methods. In many cases, calculating bounds under minimal assumptions may seem to be a 
meaningless exercise because the bounds are often quite wide and may not exclude the null 
of no treatment effect as seen with the “no assumptions” bounds in Section 2. On the 
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contrary, in settings like this Robins and Greenland (1996) write: “Some argue against 
reporting bounds for non-identifiable parameters, because bounds are often so wide as to be 
useless for making public health decisions. But we view the latter problem as a reason for 
reporting bounds in conjunction with other analyses: Wide bounds make clear that the 
degree to which public health decisions are dependent on merging the data with strong prior 
beliefs.”
Bounds may be narrowed by reducing the feasible region of the optimization problem. This 
may be accomplished by considering further assumptions that place restrictions on either the 
distributions of the potential outcomes, the distributions of the observable random variables, 
or both. Assumptions that place restrictions on the observable random variables may have 
implications which are testable. If the observed data provide evidence against any 
assumptions being considered, bounds should be computed without making these 
assumptions. Those assumptions without testable implications can only be determined to be 
plausible or not by subject matter experts.
A potentially less conservative approach to computing bounds is to make untestable 
assumptions which identify the causal estimand and then assess the robustness of inference 
drawn to departures from these assumptions in a sensitivity analysis. A general guideline for 
specifying the sensitivity analysis parameters representing these departures is to choose 
parameters that are easily interpretable to subject matter experts. Parameter specification 
will depend on whether or not sensitivity analysis is conducted by directly modeling the 
association of an unmeasured confounder U with treatment selection and the potential 
outcomes. Sensitivity analyses based on this approach are applicable when the existence of 
U is known and there is some historical knowledge of the magnitude association of U with Z 
and the potential outcomes (Robins, 1999; Brumback et al., 2004). Otherwise, alternative 
approaches based on directly modeling the unobserved potential outcome distributions may 
be preferred. A second guiding principle should be to avoid specifications of sensitivity 
parameters that place restrictions on the distributions of observable random variables that 
are not empirically supported. A third consideration when conducting sensitivity analysis 
concerns determining a plausible region of the sensitivity parameters. That the region be 
chosen prior to data analysis is in general necessary for inference, such as described in 
Section 7, to be valid. Choice of the region of the sensitivity parameters may be dictated by 
whether one wants to consider only mild or also severe departures from the identifying 
assumptions. If the identifying assumption in question is considered plausible, then it may 
be that only mild departures from the assumption are deemed necessary for the sensitivity 
analysis. In this case, subject matter experts can be consulted to determine, prior to data 
analysis, a plausible region for the sensitivity parameters. If, on the other hand, severe 
departures from untestable identifying assumptions are to be entertained, sensitivity analyses 
should be conducted over all possible values of the sensitivity parameters. Sensitivity 
analyses which consider all possible full data distributions that marginalize to the observed 
data distribution will yield ignorance regions containing the bounds.
Though the examples presented here demonstrate the broad scope of scenarios where 
bounds and sensitivity analysis methods have been derived and employed to draw inference 
about treatment effects, they certainly are not exhaustive of all settings where these methods 
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have been developed. For instance, VanderWeele, Mukherjee and Chen (2012) consider 
sensitivity analysis to unmeasured confounding for causal interaction effects. Bounds and 
sensitivity analysis methods have also recently been considered in the presence of 
interference, that is, in settings where treatment of one individual may affect the outcome of 
another individual, such as in social networks (Ver Steeg and Galstyan, 2010; VanderWeele, 
2011b; Manski, 2013). For studies where sensitivity analyses are planned or anticipated, 
Rosenbaum and colleagues have examined how aspects of study design and the choice of 
statistical tests or estimators may affect the power or precision of the sensitivity analyses to 
be conducted (Heller, Rosenbaum and Small, 2009; Rosenbaum, 2010a; 2010b; 2011).
Bounds and sensitivity analyses of treatment effects have been utilized in various 
substantive settings, such as biomedical research (e.g., Cole et al., 2005; Rerks-Ngarm et al., 
2009; VanderWeele and Hernández-Diaz, 2011; Hu et al., 2012) and economics (e.g., 
Heckman, 2001; Sianesi, 2004; Armstrong, Guay and Weber, 2010). Nonetheless, despite 
the wide range of settings in which these methods are applicable, their use in substantive 
settings remains somewhat limited in frequency. Given the large amount of literature 
detailing their broad scope of applicability and that formal inferential methods for partially 
identifiable parameters are now available, hopefully these approaches will be employed with 
greater frequency in substantive settings in the future.
The sensitivity analyses described throughout this paper focus on departures from untestable 
assumptions which identify treatment effects. Other types of sensitivity analyses might be 
considered as well, for example, to assess how robust inferences are to various analytical 
decisions that are invariably made in data analysis. Rosenbaum (2002, Section 11.9) refers 
to such assessment as “stability analysis,” in contrast to the types of sensitivity analyses 
discussed above. See Rosenbaum (1999, 2002) and Morgan and Winship (2007, Section 6.2) 
for further discussion regarding various types of sensitivity analyses beyond the type 
considered here.
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Graphical depiction of the bounds and sensitivity analysis model described in Sections 3.3 
and 3.4. The solid thin line with negative slope represents a set of joint distribution functions 
of (Z, S(1), S(0), Y(1), Y(0)) that all give rise to the same distribution of the observable 
random variables (Z, S, Y). The four dotted curves depict the log odds ratio selection model 
for γ = 0, 1, 2, 4. The γ = 0 model is equivalent to the no selection model. Each selection 
model identifies exactly one pair of expectations from this set, rendering the principal effect 
(10) identifiable. The thick black lines on the edge of the unit square correspond to the lower 
bound of the principal effect.
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Estimated ignorance regions irf0(β, Γ) and 95% pointwise uncertainty regions URp(β, Γ) for 
the pertussis vaccine example in Section 7.3. The principal effect (10) is denoted β and Γ = 
[−γu, γu] for γu along the horizontal axis. The curve given by the lower boundary of the area 
with black slanted lines corresponds to βl̂, the minimum of the estimated ignorance regions, 
and the upper bound of the area with black slanted lines corresponds to β̂u, the maximum of 
the estimated ignorance region. The curve given by the lower (upper) boundary of the gray 
shaded area corresponds to the minimum (maximum) of the 95% pointwise uncertainty 
region.
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Table 1
Pertussis vaccine study data: Estimated ignorance regions and 95% pointwise and strong uncertainty regions 
of β = E[Y(1) − Y(0)|SP0 = (1, 1)] for different Γ
Γ irf0(β, Γ) URp(β, Γ) URs(β, Γ)
[−3, 3] [−0.49, −0.17] [−0.58, −0.07] [−0.59, −0.06]
[−5, 5] [−0.55, −0.15] [−0.66, −0.05] [−0.69, −0.03]
[−10, 10] [−0.57, −0.15] [−0.70, −0.04] [−0.73, −0.02]
(−∞, ∞) [−0.57, −0.15] [−0.70, −0.04] [−0.73, −0.02]
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